Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2015 2
2016 1
2017 5
2018 1
2019 2
2020 3
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for label i. barriga
Your search for Mabel I. Barroga retrieved no results
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A. Sledge GW Jr, et al. J Clin Oncol. 2017 Sep 1;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585. Epub 2017 Jun 3. J Clin Oncol. 2017. PMID: 28580882 Clinical Trial.
Patients were randomly assigned 2:1 to receive abemaciclib or placebo (150 mg twice daily) on a continuous schedule and fulvestrant (500 mg, per label). The primary end point was investigator-assessed progression-free survival (PFS), and key secondary end points included o …
Patients were randomly assigned 2:1 to receive abemaciclib or placebo (150 mg twice daily) on a continuous schedule and fulvestrant (500 mg, …
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, Goetz MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg R, Sohn J, Guarneri V, Cortés J, Hamilton E, André V, Wei R, Barriga S, Sherwood S, Forrester T, Munoz M, Shahir A, San Antonio B, Nabinger SC, Toi M, Johnston SRD, O'Shaughnessy J; monarchE Committee Members. Harbeck N, et al. Ann Oncol. 2021 Dec;32(12):1571-1581. doi: 10.1016/j.annonc.2021.09.015. Epub 2021 Oct 14. Ann Oncol. 2021. PMID: 34656740 Free article. Clinical Trial.
Here, we present results of the prespecified primary outcome analysis and an additional follow-up analysis. PATIENTS AND METHODS: This global, phase III, open-label trial randomized (1 : 1) 5637 patients to adjuvant ET for 5 years abemaciclib for 2 years. ...
Here, we present results of the prespecified primary outcome analysis and an additional follow-up analysis. PATIENTS AND METHODS: This globa …
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A. Sledge GW Jr, et al. JAMA Oncol. 2020 Jan 1;6(1):116-124. doi: 10.1001/jamaoncol.2019.4782. JAMA Oncol. 2020. PMID: 31563959 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomized 2:1 to receive abemaciclib or placebo, 150 mg, every 12 hours on a continuous schedule plus fulvestrant, 500 mg, per label. Randomization was stratified based on site of metastasis (visceral, bone only, or other) and resistance to pr …
INTERVENTIONS: Patients were randomized 2:1 to receive abemaciclib or placebo, 150 mg, every 12 hours on a continuous schedule plus fulvestr …
Spinal premotor interneurons controlling antagonistic muscles are spatially intermingled.
Ronzano R, Skarlatou S, Barriga BK, Bannatyne BA, Bhumbra GS, Foster JD, Moore JD, Lancelin C, Pocratsky AM, Özyurt MG, Smith CC, Todd AJ, Maxwell DJ, Murray AJ, Pfaff SL, Brownstone RM, Zampieri N, Beato M. Ronzano R, et al. Elife. 2022 Dec 13;11:e81976. doi: 10.7554/eLife.81976. Elife. 2022. PMID: 36512397 Free PMC article.
The neuroanatomical arrangement of motor and premotor neurons into topographic patterns related to their controlled muscles is thought to facilitate how information is processed by spinal circuits. Rabies retrograde monosynaptic tracing has been used to label premotor inte …
The neuroanatomical arrangement of motor and premotor neurons into topographic patterns related to their controlled muscles is thought to fa …
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M. Rugo HS, et al. Oncologist. 2021 Jan;26(1):e53-e65. doi: 10.1002/onco.13531. Epub 2020 Oct 9. Oncologist. 2021. PMID: 32955138 Free PMC article.
Clinicians should be aware of and implement management strategies, including dose adjustments according to local labels, for commonly occurring and serious adverse events to ensure continued treatment and optimize clinical benefit/risk ratio....
Clinicians should be aware of and implement management strategies, including dose adjustments according to local labels, for commonly …
Spontaneous charged lipid transfer between lipid vesicles.
Richens JL, Tyler AII, Barriga HMG, Bramble JP, Law RV, Brooks NJ, Seddon JM, Ces O, O'Shea P. Richens JL, et al. Sci Rep. 2017 Oct 3;7(1):12606. doi: 10.1038/s41598-017-12611-0. Sci Rep. 2017. PMID: 28974701 Free PMC article.
A donor/acceptor vesicle system is employed, where neutrally charged acceptor vesicles are fluorescently labelled with the electrostatic membrane probe Fluoresceinphosphatidylethanolamine (FPE). ...
A donor/acceptor vesicle system is employed, where neutrally charged acceptor vesicles are fluorescently labelled with the electrosta …
Revealing Population Heterogeneity in Vesicle-Based Nanomedicines Using Automated, Single Particle Raman Analysis.
Saunders C, Foote JEJ, Wojciechowski JP, Cammack A, Pedersen SV, Doutch JJ, Barriga HMG, Holme MN, Penders J, Chami M, Najer A, Stevens MM. Saunders C, et al. ACS Nano. 2023 Jun 27;17(12):11713-11728. doi: 10.1021/acsnano.3c02452. Epub 2023 Jun 6. ACS Nano. 2023. PMID: 37279338 Free PMC article.
Here, we present an analytical technique to provide such information, while measuring the nanocarrier and cargo simultaneously with label-free, nondestructive single particle automated Raman trapping analysis (SPARTA). ...We then confirmed the suitability of our technique …
Here, we present an analytical technique to provide such information, while measuring the nanocarrier and cargo simultaneously with label …
Mex3a Marks a Slowly Dividing Subpopulation of Lgr5+ Intestinal Stem Cells.
Barriga FM, Montagni E, Mana M, Mendez-Lago M, Hernando-Momblona X, Sevillano M, Guillaumet-Adkins A, Rodriguez-Esteban G, Buczacki SJA, Gut M, Heyn H, Winton DJ, Yilmaz OH, Attolini CS, Gut I, Batlle E. Barriga FM, et al. Cell Stem Cell. 2017 Jun 1;20(6):801-816.e7. doi: 10.1016/j.stem.2017.02.007. Epub 2017 Mar 9. Cell Stem Cell. 2017. PMID: 28285904 Free PMC article.
Here we report unanticipated heterogeneity within the Lgr5+ ISC pool. We found that expression of the RNA-binding protein Mex3a labels a slowly cycling subpopulation of Lgr5+ ISCs that contribute to all intestinal lineages with distinct kinetics. ...
Here we report unanticipated heterogeneity within the Lgr5+ ISC pool. We found that expression of the RNA-binding protein Mex3a labels …
Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Eichstadt S, Barriga M, Ponakala A, Teng C, Nguyen NT, Siprashvili Z, Nazaroff J, Gorell ES, Chiou AS, Taylor L, Khuu P, Keene DR, Rieger K, Khosla RK, Furukawa LK, Lorenz HP, Marinkovich MP, Tang JY. Eichstadt S, et al. JCI Insight. 2019 Oct 3;4(19):e130554. doi: 10.1172/jci.insight.130554. JCI Insight. 2019. PMID: 31578311 Free PMC article. Clinical Trial.
BACKGROUNDRecessive dystrophic epidermolysis bullosa (RDEB) patients have mutations in the COL7A1 gene and thus lack functional type VII collagen (C7) protein; they have marked skin fragility and blistering. This single-center phase 1/2a open-label study evaluated the long …
BACKGROUNDRecessive dystrophic epidermolysis bullosa (RDEB) patients have mutations in the COL7A1 gene and thus lack functional type VII col …
18 results